ZA200509152B - Bicalutamide forms, compositions, and processes thereof - Google Patents
Bicalutamide forms, compositions, and processes thereof Download PDFInfo
- Publication number
- ZA200509152B ZA200509152B ZA200509152A ZA200509152A ZA200509152B ZA 200509152 B ZA200509152 B ZA 200509152B ZA 200509152 A ZA200509152 A ZA 200509152A ZA 200509152 A ZA200509152 A ZA 200509152A ZA 200509152 B ZA200509152 B ZA 200509152B
- Authority
- ZA
- South Africa
- Prior art keywords
- bicalutamide
- granulate
- dosage form
- pharmaceutical composition
- micronized
- Prior art date
Links
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical group C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 title claims description 164
- 239000000203 mixture Substances 0.000 title claims description 54
- 238000000034 method Methods 0.000 title claims description 43
- 229960000997 bicalutamide Drugs 0.000 claims description 155
- 239000008187 granular material Substances 0.000 claims description 82
- 239000002775 capsule Substances 0.000 claims description 42
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 39
- 239000002245 particle Substances 0.000 claims description 30
- 238000004090 dissolution Methods 0.000 claims description 27
- 239000008194 pharmaceutical composition Substances 0.000 claims description 25
- 239000007884 disintegrant Substances 0.000 claims description 18
- 239000007787 solid Substances 0.000 claims description 16
- 238000005550 wet granulation Methods 0.000 claims description 15
- 238000007909 melt granulation Methods 0.000 claims description 14
- 239000002552 dosage form Substances 0.000 claims description 13
- 239000006186 oral dosage form Substances 0.000 claims description 12
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 11
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 11
- 239000011230 binding agent Substances 0.000 claims description 8
- 239000003960 organic solvent Substances 0.000 claims description 7
- 238000011049 filling Methods 0.000 claims description 6
- 239000003098 androgen Substances 0.000 claims description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 5
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 4
- 239000000194 fatty acid Substances 0.000 claims description 4
- 229930195729 fatty acid Natural products 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- -1 fatty acid ester Chemical class 0.000 claims description 3
- 238000003801 milling Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 238000009736 wetting Methods 0.000 claims description 3
- 239000003826 tablet Substances 0.000 description 71
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 239000007903 gelatin capsule Substances 0.000 description 13
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 12
- 239000013543 active substance Substances 0.000 description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
- 229920003109 sodium starch glycolate Polymers 0.000 description 10
- 229940079832 sodium starch glycolate Drugs 0.000 description 10
- 239000008109 sodium starch glycolate Substances 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 9
- 238000007908 dry granulation Methods 0.000 description 9
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 239000000314 lubricant Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 7
- 229960001021 lactose monohydrate Drugs 0.000 description 7
- 239000008213 purified water Substances 0.000 description 7
- 229940083575 sodium dodecyl sulfate Drugs 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 238000005469 granulation Methods 0.000 description 6
- 230000003179 granulation Effects 0.000 description 6
- 229940069328 povidone Drugs 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 238000007906 compression Methods 0.000 description 5
- 230000006835 compression Effects 0.000 description 5
- 239000000945 filler Substances 0.000 description 5
- 229960001375 lactose Drugs 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- 229940057948 magnesium stearate Drugs 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 235000012239 silicon dioxide Nutrition 0.000 description 4
- LKJPYSCBVHEWIU-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide Chemical compound C=1C=C(C#N)C(C(F)(F)F)=CC=1NC(=O)C(O)(C)CS(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-UHFFFAOYSA-N 0.000 description 3
- 239000007963 capsule composition Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 229960000913 crospovidone Drugs 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 239000005414 inactive ingredient Substances 0.000 description 3
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 3
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000007962 solid dispersion Substances 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000007891 compressed tablet Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000010419 fine particle Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000008240 homogeneous mixture Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 239000011343 solid material Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 description 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Substances CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 229940097647 casodex Drugs 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000011928 denatured alcohol Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000005429 filling process Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 125000005908 glyceryl ester group Chemical group 0.000 description 1
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000012943 hotmelt Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000008203 oral pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940113116 polyethylene glycol 1000 Drugs 0.000 description 1
- 229940068917 polyethylene glycols Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000000634 powder X-ray diffraction Methods 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47022403P | 2003-05-14 | 2003-05-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200509152B true ZA200509152B (en) | 2007-04-25 |
Family
ID=33452382
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200509152A ZA200509152B (en) | 2003-05-14 | 2005-11-11 | Bicalutamide forms, compositions, and processes thereof |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20050008691A1 (enExample) |
| EP (1) | EP1622604A1 (enExample) |
| JP (1) | JP2006528221A (enExample) |
| AU (1) | AU2004238038A1 (enExample) |
| CA (1) | CA2525318A1 (enExample) |
| FI (1) | FI7526U1 (enExample) |
| NO (1) | NO20055943L (enExample) |
| WO (1) | WO2004100944A1 (enExample) |
| ZA (1) | ZA200509152B (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60234812D1 (de) | 2001-01-29 | 2010-02-04 | Shionogi & Co | Arzneipräparat, das als wirkstoff 5-methyl-1-phenyl-2-(1h)-pyridon enthält |
| US20040063782A1 (en) * | 2002-09-27 | 2004-04-01 | Westheim Raymond J.H. | Bicalutamide forms |
| WO2006006736A1 (ja) * | 2004-07-14 | 2006-01-19 | Sumitomo Chemical Company, Limited | ビカルタミドの晶析方法 |
| US20080177109A1 (en) * | 2005-03-29 | 2008-07-24 | Usv Limited | Novel Process for Preparation of Bicalutamide |
| US7785629B2 (en) * | 2005-06-21 | 2010-08-31 | Helm Ag | Bicalutamide-adsorbates, process for preparing same, and pharmaceutical compositions thereof |
| US20070014854A1 (en) * | 2005-07-15 | 2007-01-18 | Ilan Zalit | Novel granulation process |
| US20070014864A1 (en) * | 2005-07-15 | 2007-01-18 | Teva Pharmaceutical Industries, Ltd. | Novel pharmaceutical granulate |
| US20070014853A1 (en) * | 2005-07-15 | 2007-01-18 | Ilan Zalit | Pharmaceutical dosage form containing novel pharmaceutical granulate |
| WO2007011349A1 (en) * | 2005-07-15 | 2007-01-25 | Teva Pharmaceutical Industries Ltd. | Novel granulation process and granulate produced therefrom |
| JP2007063225A (ja) | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
| NZ591443A (en) * | 2005-09-22 | 2013-04-26 | Intermune Inc | Granule formation of pirfenidone and pharmaceutically acceptable excipients |
| CZ299577B6 (cs) * | 2005-12-20 | 2008-09-03 | Interpharma Praha, A. S. | Zpusob výroby vysoce cistého 4-kyano-3-trifluoromethyl-N-(3-p-fluorfenylsulfonyl-2-hydroxy-2-methylpropionyl) anilinu |
| US20070148245A1 (en) * | 2005-12-22 | 2007-06-28 | Ilan Zalit | Compressed solid dosage forms with drugs of low solubility and process for making the same |
| JP5302012B2 (ja) | 2006-03-08 | 2013-10-02 | タケダ カリフォルニア インコーポレイテッド | グルコキナーゼ活性剤 |
| JP5386350B2 (ja) | 2006-05-31 | 2014-01-15 | タケダ カリフォルニア インコーポレイテッド | グルコキナーゼ活性剤としての、インダゾールおよびイソインドール誘導体 |
| CN101478963A (zh) * | 2006-07-07 | 2009-07-08 | 万能药生物有限公司 | 包含比卡鲁胺的药物组合物及其用法 |
| US20080045600A1 (en) * | 2006-08-17 | 2008-02-21 | Gawande Rahul S | Bicalutamide compositions |
| AU2007295178B2 (en) * | 2006-09-15 | 2013-04-18 | Echo Pharmaceuticals B.V. | Granulate containing a pharmaceutically active substance and anemulsifier and method for its manufacture |
| EP2063861B1 (en) * | 2006-09-15 | 2015-02-25 | Echo Pharmaceuticals B.V. | Dosage unit for sublingual, buccal or oral administration of water-insoluble pharmaceutically active substances |
| JP5419706B2 (ja) | 2006-12-20 | 2014-02-19 | タケダ カリフォルニア インコーポレイテッド | グルコキナーゼアクチベーター |
| GB0702826D0 (en) * | 2007-02-14 | 2007-03-28 | Pliva Istrazivanje I Razvoj D | Preparation and composition of solid dosage form containing Bicalutamide |
| US8173645B2 (en) | 2007-03-21 | 2012-05-08 | Takeda San Diego, Inc. | Glucokinase activators |
| CN102238941A (zh) * | 2008-09-17 | 2011-11-09 | 迈兰实验室公司 | 颗粒、制备它们的方法和包含它们的药物产品 |
| CA2937365C (en) | 2016-03-29 | 2018-09-18 | F. Hoffmann-La Roche Ag | Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same |
| US20190008868A1 (en) * | 2017-04-28 | 2019-01-10 | Asana Biosciences, Llc | Formulations, methods, kits, and dosage forms for treating atopic dermatitis and for improved stability of an active pharmaceutical ingredient |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LU88769I2 (fr) * | 1982-07-23 | 1996-11-05 | Zeneca Ltd | Bicalutamide et ses sels et esters pharmaceutiquement acceptables (Casodex (R)) |
| ATE108996T1 (de) * | 1988-02-25 | 1994-08-15 | Brocades Pharma Bv | Verfahren zur herstellung eines pharmazeutischen granulats. |
| FR2684298B1 (fr) * | 1991-12-03 | 1994-03-11 | Rhone Poulenc Rorer Sa | Nouvelles compositions pharmaceutiques solides a base de derives de lapiperidine substitues en 1,4. |
| WO1995019770A1 (en) * | 1994-01-21 | 1995-07-27 | Sepracor, Inc. | Methods and compositions for treating androgen-dependent diseases using optically pure r-(-)-casodex |
| AU7723198A (en) * | 1997-06-04 | 1998-12-21 | University Of Tennessee Research Corporation, The | Non-steroidal radiolabeled agonist/antagonist compounds and their use in prostate cancer imaging |
| HU223950B1 (hu) | 1999-06-10 | 2005-03-29 | Richter Gedeon Vegyészeti Gyár Rt. | Eljárás a racém, valamint az R-(-)- és S-(+)-N-[4-ciano-3-(trifluor-metil)-fenil]-3-[(4-fluor-fenil)-szulfonil]-2-hidroxi-2-metil-propánsavamid előállítására |
| DE60206889T2 (de) * | 2001-02-27 | 2006-07-27 | Astrazeneca Ab | Pharmazeutische formulierung enthaltend bicalutamid |
| KR20030087048A (ko) * | 2001-04-02 | 2003-11-12 | 아스트라제네카 아베 | 4-시아노-트리플루오로-3-(4-플루오로페닐설포닐)-2-히드록시-2-메틸프로피오노-ｍ 톨루이다이드 및 ｐｖｐ를포함하는 고체 약학 조성물 |
| US6458769B1 (en) * | 2001-06-25 | 2002-10-01 | Astrazeneca Ab | Amorphous compound |
| SE0103838D0 (sv) * | 2001-11-16 | 2001-11-16 | Astrazeneca Ab | Pharmaceutical formulation & product |
| GB0216700D0 (en) * | 2002-07-18 | 2002-08-28 | Astrazeneca Ab | Process |
| US20040063782A1 (en) * | 2002-09-27 | 2004-04-01 | Westheim Raymond J.H. | Bicalutamide forms |
-
2004
- 2004-05-11 US US10/842,632 patent/US20050008691A1/en not_active Abandoned
- 2004-05-13 CA CA002525318A patent/CA2525318A1/en not_active Abandoned
- 2004-05-13 EP EP04732612A patent/EP1622604A1/en not_active Withdrawn
- 2004-05-13 AU AU2004238038A patent/AU2004238038A1/en not_active Abandoned
- 2004-05-13 WO PCT/EP2004/005189 patent/WO2004100944A1/en not_active Ceased
- 2004-05-13 JP JP2006529819A patent/JP2006528221A/ja not_active Withdrawn
-
2005
- 2005-11-11 ZA ZA200509152A patent/ZA200509152B/en unknown
- 2005-12-14 NO NO20055943A patent/NO20055943L/no not_active Application Discontinuation
-
2006
- 2006-10-25 FI FI20060440U patent/FI7526U1/fi not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004100944A1 (en) | 2004-11-25 |
| NO20055943L (no) | 2006-01-25 |
| CA2525318A1 (en) | 2004-11-25 |
| JP2006528221A (ja) | 2006-12-14 |
| AU2004238038A1 (en) | 2004-11-25 |
| FI7526U1 (fi) | 2007-06-12 |
| FIU20060440U0 (fi) | 2006-10-25 |
| EP1622604A1 (en) | 2006-02-08 |
| US20050008691A1 (en) | 2005-01-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200509152B (en) | Bicalutamide forms, compositions, and processes thereof | |
| US6511681B2 (en) | Aqueous solubility pharmaceutical formulations | |
| Roblegg et al. | Development of sustained-release lipophilic calcium stearate pellets via hot melt extrusion | |
| EP2442799B2 (en) | Solid pharmaceutical composition comprising rivaroxaban | |
| US20190125725A1 (en) | Pharmaceutical compositions comprising brivaracetam | |
| US5512302A (en) | Pharmaceutical process using starch | |
| EP2167047A2 (en) | Process for forming solid oral dosage forms of angiotensin ii receptor antagonists | |
| EA017941B1 (ru) | Суспензия, содержащая микрочастицы эзетимиба | |
| WO2003082262A2 (en) | Compositions of venlafaxine base | |
| EP2050436A1 (en) | Pharmaceutical composition containing dutasteride | |
| EP3157506B1 (en) | Taste-masked oral pharmaceutical composition | |
| JPH11246404A (ja) | 吸収を改善した医薬組成物 | |
| WO2023059296A1 (en) | A tablet comprising micronized brexpiprazole | |
| CN104254321A (zh) | 稳定性提高的药物制剂 | |
| JP3547009B1 (ja) | ５−［（１ｚ，２ｅ）−２−メチル−３−フェニル−２−プロペニリデン］−４−オキソ−２−チオキソ−３−チアゾリジン酢酸の新規結晶、その製造方法およびその結晶を有効成分とする医薬 | |
| WO2007073389A1 (en) | Compressed solid dosage forms with drugs of low solubility and process for making the same | |
| WO2014009817A1 (en) | Pharmaceutical composition of febuxostat | |
| WO2020045456A1 (ja) | 薬物含有粒子 | |
| US20070148245A1 (en) | Compressed solid dosage forms with drugs of low solubility and process for making the same | |
| WO2025046606A1 (en) | Granules of mavacamten for oral administration | |
| Hejduk et al. | Impact of co-processing on functional attributes of innovative pharmaceutical excipients | |
| JP2025526729A (ja) | ナポラフェニブを含む非晶質固体分散体 | |
| AU2017228681B2 (en) | Apixaban formulations | |
| EP4412595A1 (en) | A tablet comprising micronized brexpiprazole | |
| EP4374856A1 (en) | A process for tablets comprising brexpiprazole |